Copyright
©The Author(s) 2023.
World J Gastroenterol. May 7, 2023; 29(17): 2571-2599
Published online May 7, 2023. doi: 10.3748/wjg.v29.i17.2571
Published online May 7, 2023. doi: 10.3748/wjg.v29.i17.2571
Table 1 Barcelona Clinic Liver Cancer staging system and treatment strategy
Stage | Very early stage (0) | Early stage (A) | Intermediate stage (B) | Advanced stage (C) | Terminal stage (D) |
Characteristics | Single nodule < 2 cm, preserved liver function, ECOG PS 0 | Single or 2-3 nodules < 3 cm, preserved liver function, ECOG PS 0 | Multinodular, unresectable, preserved liver function, ECOG PS 0 | Portal invasion/extrahepatic spread, preserved liver function, ECOG PS 1-2 | Not transplantable HCC, end-stage liver function, ECOG PS 3-4 |
Treatment | Ablation, resection, transplant | Chemoembolization | Systemic therapy | Best supportive care | |
Survival | > 5 yr | > 2.5 yr | > 2 yr | 3 mo |
- Citation: Villarruel-Melquiades F, Mendoza-Garrido ME, García-Cuellar CM, Sánchez-Pérez Y, Pérez-Carreón JI, Camacho J. Current and novel approaches in the pharmacological treatment of hepatocellular carcinoma. World J Gastroenterol 2023; 29(17): 2571-2599
- URL: https://www.wjgnet.com/1007-9327/full/v29/i17/2571.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i17.2571